← Back to headlines
ImmunityBio Skyrockets on Anktiva-Driven Revenue Jump
ImmunityBio (IBRX) stock has surged significantly after its drug Anktiva propelled a 671% increase in revenue.
25 Feb, 06:44 — 25 Feb, 06:44
Sources
Showing 1 of 1 sources
Related Stories
Amazon's First Customer Receipt Goes Viral, Bezos and Musk React
just now
Four Arrested for Selling P102 Million in Counterfeit Anti-Cancer Medicine in Makati
just now
Oil Traffic Through Danish Straits Reaches Historic Highs, Raising Safety and Pollution Concerns
13m ago
Poland Increases Subsidies for Employees with Disabilities in 2026
26m ago